Syros Pharmaceuticals Inc (SYRS) Expected to Post Quarterly Sales of $720,000.00
Wall Street analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce $720,000.00 in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $350,000.00 and the highest estimate coming in at $1.75 million. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.89 million for the current financial year, with estimates ranging from $750,000.00 to $4.25 million. For the next fiscal year, analysts anticipate that the company will post sales of $2.62 million, with estimates ranging from $600,000.00 to $7.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.33 million.
A number of large investors have recently modified their holdings of SYRS. BlackRock Inc. raised its stake in Syros Pharmaceuticals by 70.4% in the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock worth $16,169,000 after buying an additional 654,094 shares in the last quarter. ARK Investment Management LLC raised its stake in Syros Pharmaceuticals by 19.6% in the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock worth $18,373,000 after buying an additional 294,663 shares in the last quarter. Millennium Management LLC raised its stake in Syros Pharmaceuticals by 129.3% in the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after buying an additional 211,696 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals in the second quarter worth approximately $1,703,000. Finally, Renaissance Technologies LLC purchased a new position in Syros Pharmaceuticals in the second quarter worth $1,684,000. 60.70% of the stock is owned by institutional investors.
Shares of Syros Pharmaceuticals stock traded down $0.63 on Monday, hitting $6.79. 10,268 shares of the company traded hands, compared to its average volume of 186,292. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $17.50. The company has a market capitalization of $400.82 million, a PE ratio of -3.39 and a beta of -1.96.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Read More: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.